A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C
 Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a
 (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve undetectable hepatitis C virus ribonucleic
 acid (HCV RNA) 12 weeks after the last planned dose of study drug.
Inclusion Criteria:

 -  Participants must have chronic, genotype 1a or 1b, hepatitis C with HCV RNA greater
 than (>) 1000 international units per milliliter (IU/mL)

 -  Population A: HCV Pegylated interferon (Peg-IFN)/RBV treatment naive (received no
 prior HCV therapy)or Peg-IFN/RBV prior treatment with relapse

 -  Population B: Peg-IFN/RBV prior null or partial responder

 -  Participants must not have achieved undetectable HCV RNA 24 weeks after the last
 planned dose of study drug (SVR24) after at least 1 prior course of Peg IFN/RBV
 therapy of standard duration

 -  Participant must have positive HIV antibody at Screening

 -  Participant must have a diagnosis of HIV-1 infection >6 months before Screening

 -  Participants should be taking 1 of the following permissible highly active
 antiretroviral therapy (HAART) regimens for HIV continuously for 12 weeks prior to
 screening:

 -  Atripla® or equivalent components (efavirenz, tenofovir, emtricitabine)

 -  Efavirenz plus Epzicom® (abacavir, lamivudine) or equivalent components

 -  Boosted atazanavir (atazanavir with ritonavir) plus Truvada® (tenofovir,
 emtricitabine) or equivalent components

 -  Boosted atazanavir plus Epzicom®, or equivalent components

 -  Raltegravir plus Truvada®, or equivalent components

 -  Raltegravir plus Epzicom®, or equivalent components

 -  Cluster of differentiation 4 (CD4) counts and human immunodeficiency virus Type 1
 (HIV-1) ribonucleic acid (RNA) meeting acceptable criteria at Screening as specified
 in the protocol

 -  Laboratory values within acceptable ranges at Screening as specified in the protocol

 Exclusion Criteria:

 -  Subjects anticipating a need to switch HAART regimens within 14 weeks after Day 1 or
 any switches occurring 12 weeks prior to Day 1

 -  Use of azidothymidine (AZT), didanosine (ddI) or stavudine (d4T) nucleosides

 -  Contraindications to any planned HAART component as per the respective drug labeling
 information

 -  Contraindications to Peg-IFN or RBV

 -  Evidence of hepatic decompensation

 -  Clinical suspicion of acute hepatitis

 -  Any other cause of liver disease in addition to hepatitis C

 -  History of organ transplantation (except cornea and skin)

 -  Autoimmune-mediated disease

 -  Participated in any investigational drug study within 90 days before Day 1

 -  Previous treatment with an HCV protease inhibitor